Drugs / belapectin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02575404 | May 2016 → Jan 2021 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT02117362 | May 2014 → Nov 2018 | metastatic melanoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04987996 | Jul 2023 → Jul 2027 | head and neck squamous cell carcinoma, metastatic melanoma | Providence Health & Services | Withdrawn | No outcome recorded |
| Phase 2 | NCT02407041 | Sep 2015 → Mar 2018 | psoriasis | Galectin Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04365868 | Jun 2020 → Mar 2025 | cirrhosis of liver, esophageal varices, metabolic dysfunction-associated steatohepatitis | Galectin Therapeutics Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04332432 Comparator | Jun 2020 → Mar 2022 | — | Galectin Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01899859 Comparator | Jul 2013 → Feb 2015 | metabolic dysfunction-associated steatohepatitis | Galectin Therapeutics Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02421094 Comparator | Sep 2015 → Sep 2016 | metabolic dysfunction-associated steatohepatitis | Galectin Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02462967 Comparator | Jun 2015 → Oct 2017 | portal hypertension | Galectin Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | belapectin | “GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypertension in rats and was safe and well tolerated in phase 1 studies.” PMID 31812510 ↗ Dec 2019 |
| Known as | GR MD 02 | “GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3” NCT02462967 ↗ |
| Action | Inhibit | “galectin-3 inhibitor” NCT02117362 ↗1“Galectin-3 inhibitor” CHEMBL4297577 ↗ |
| Modality | Other / unclassified | “a complex carbohydrate drug” NCT02462967 ↗ |
| Route | Intravenous | “when administered intravenously” NCT01899859 ↗ |
| Target | LGALS3 | “Galectin-3 inhibitor” CHEMBL4297577 ↗ |